Global population frequencies of NAT2 star alleles observed in three large biobanks
Authors:
Preprint
Abstract
NAT2 is an important pharmacogene which encodes the N-acetyltransferase 2 enzyme that is involved in the metabolism of multiple medications, and variants in this gene can affect patient response to these medications. CPIC has published a clinical guideline for prescribing hydralazine using NAT2 genotypes. Just prior to the guideline, updated NAT2 star allele numbering and definitions were released, differing somewhat from the historical nomenclature. Clinical pharmacogenomic testing panels often test for the most common star alleles, so knowledge of the most common updated NAT2 star alleles is critical for the implementation of the CPIC NAT2/hydralazine guideline. We first determine NAT2 diplotype frequencies from UK Biobank (UKBB) 200k phased genomes, then analyzed allele, diplotype, and phenotype population frequencies from the All of Us Research program, PennMedicine BioBank (PMBB) and UKBB 500k datasets. We found that analyzing NAT2 diplotypes from phased data provides critical information for algorithms designed to predict diplotypes from unphased data. We observed that NAT2*5 , *6 , and *4 were the most common star alleles in that order, and the top 11 most frequent NAT2 star alleles were the same across all biobanks. However, differences in star allele frequencies across biogeographical populations were observed. The largest difference led to a higher frequency of NAT2 poor metabolizer phenotypes as compared to rapid and intermediate metabolizer phenotypes in all global populations except in the EAS population, where NAT2 poor metabolizers were in the minority.Keywords
Funding Information
- National Institutes of Health (U24HG013077)
- National Institutes of Health (U24HG010615)
This publication has 33 references indexed in Scilit:
- Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine TherapyClinical Pharmacology & Therapeutics, 2025
- Report on the 2024 international phase II/N-acetyltransferase workshopArchives of Toxicology, 2025
- Characterization of NAT, GST, and CYP2E1 Genetic Variation in Sub‐Saharan African Populations: Implications for Treatment of Tuberculosis and Other DiseasesClinical Pharmacology & Therapeutics, 2025
- Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented PopulationClinical Pharmacology & Therapeutics, 2024
- Frequencies of pharmacogenomic alleles across biogeographic groups in a large-scale biobankThe American Journal of Human Genetics, 2023
- TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics KnowledgebaseThe Journal of Molecular Diagnostics, 2022
- Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin UseClinical Pharmacology & Therapeutics, 2021
- Unexpected Acetylation of Endogenous Aliphatic Amines by Arylamine N‐Acetyltransferase NAT2Angewandte Chemie International Edition, 2020
- Pharmacogenomics Clinical Annotation Tool (PharmCAT)Clinical Pharmacology & Therapeutics, 2019
- Arylamine N-Acetyltransferases – from Drug Metabolism and Pharmacogenetics to Identification of Novel Targets for Pharmacological Intervention2012